Abstract 145P
Background
Biomarkers such as fibroblast growth factor receptor (FGFR) and programmed death-ligand 1 (PD-L1) have been incorporated into the treatment paradigm of metastatic urothelial cancer (mUC). However, there are no data on the FGFR alteration rate and clinical burden of mUC patients in Taiwan. In addition, the association between FGFR status and PD-L1 expression in mUC is rarely studied.
Methods
This is a retrospective, multicenter, non-interventional study to evaluate the association between biomarkers of archived tumor and clinical outcomes including objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) in unresectable locally advanced or mUC patients between 2015-2019. FGFR alterations were detected by therascreen FGFR RGQ RT-PCR kit. PD-L1 expression was assessed by the combined positive score (CPS) in DAKO 22C3.
Results
Of the 196 patients, median age was 71, 62% were male, and more than one-third had stage III /IV tumors. FGFR alterations were detected in 13 (6.6%) patients: five patients had FGFR3 translocations and eight had FGFR3 mutations. Among FGFR (+) patients, 15 % (2/13) were PD-L1 CPS≥10, compared with 32 % (58/182) in FGFR (-) ones (Table). A negative association between FGFR status and PD-L1 expression was observed at a CPS cutoff of 5. In general, ORR was 12.2% (95% CI 8.01-17.67) among patients at any 1L treatment. It was 7.7% (95% CI 0.19-36.03) for FGFR (+) patients and 12.6% (95% CI 8.14-18.26) for FGFR (-) ones. Median PFS and OS were 3.58 months (mo.) (95% CI 2.92-4.60) and 7.39 mo. (95% CI 5.95-8.34) for 1L treatment, and 2.3 mo. (95% CI 1.45-3.32) and 5.03 mo. (95% CI 3.55-7.06) for 2L treatment. Survival outcomes were similar irrespective of FGFR status. Table: 145P
FGFR status versus PD-L1 expression in mUC
FGFR (+)(N=13) | FGFR (-)(N=183) | Overall (N=196) | Chi-Square (Nominal p value) | |
PD-L1 level, n (%) | 13 | 182 | 195 | |
PD-L1≥10 | 2 (15) | 58 (32) | 60 (31) | |
PD-L1<10 | 11 (85) | 124 (68) | 135 (69) | 0.3511 |
PD-L1≥5 | 2 (15) | 79 (43) | 81 (42) | |
PD-L1<5 | 11 (85) | 103 (57) | 114 (58) | 0.0476 |
PD-L1≥1 | 5 (38) | 111 (61) | 116 (59) | |
PD-L1<1 | 8 (62) | 71 (39) | 79 (41) | 0.1099 |
Missing | 0 | 1 | 1 |
Conclusions
This retrospective study showed high unmet needs under SoC in mUC in Taiwan, irrespective of FGFR status. The negative association between FGFR status and PD-L1 expression might be considered when deciding personalized treatment based on biomarker profiles.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Johnson & Johnson Taiwan Ltd.
Funding
Johnson & Johnson Taiwan Ltd.
Disclosure
Y. Feng: Financial Interests, Personal, Other, Consultant: Roche, Novartis, AbbVie. H. Huang: Financial Interests, Personal, Invited Speaker, Employee: Janssen Taiwan. All other authors have declared no conflicts of interest.
Resources from the same session
151P - Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer: Real-world analysis of chemotherapy use and impact on patient outcomes
Presenter: Alison Hiong
Session: Poster viewing 03
152P - An epidemiologic study on PD-L1 expression with clinical observation of initial treatment pattern in the Chinese muscle invasive urothelial bladder carcinoma patients
Presenter: Liqun Zhou
Session: Poster viewing 03
153P - Efficacy and toxicity of HER2-targeted antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review
Presenter: Tiago Padua
Session: Poster viewing 03
154P - Can urine cytology predict variants of bladder cancer?
Presenter: Hikaru Mikami
Session: Poster viewing 03
155P - Search for circulating tumor cells in patients with urothelial cancer
Presenter: Irina Kruglova
Session: Poster viewing 03
156P - The association between response to enfortumab vedotin therapy and primary tumor location in Japanese urothelial carcinoma patients
Presenter: Nozomi Hayakawa
Session: Poster viewing 03
163P - Outcomes and toxicity of fosfesterol in metastatic castration-resistant prostate cancer: Experience from a low middle income country
Presenter: Manuprasad Avaronnan
Session: Poster viewing 03
164P - F-18 PSMA-PET/CT-guided percutaneous prostate biopsy
Presenter: Rajender Kumar
Session: Poster viewing 03
165P - Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer
Presenter: Richard Kelly
Session: Poster viewing 03